Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results